Drug Use-results Surveillance of SOVRIAD capsules100mg.

Drug Use-results Surveillance of SOVRIAD capsules100mg. - Drug Use-results Surveillance of SOVRIAD capsules100mg.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015896

Enrollment

2200

Registered

2014-12-15

Start date

2013-12-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic hepatitis C who are treated with SOVRIAD capsules for the first time

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety(Adverse Drug Reaction) Effectiveness(SVR12,SVR24)	—

Countries

Japan

Contacts

Public ContactAkiko Yamamoto

Janssen Phrmaceutical K.K. Safety Risk Management Dept.

ayamamot@its.jnj.com03-4411-5173

Outcome results